FCGR3A and cancer: Since the creation of the first bispecific mAbs targeting CD16 on NK cells and CD30 on Hodgkin’s lymphoma cells more than two decades ago, bi- and trispecific mAbs have been designed to interact with erB2/CD16 in breast cancer [221], with EGFR being overexpressed in many different epithelial types of cancer [222], EPCAM in various cell carcinoma lines [223], and EPCAM/CD3 in serous endometrial cancer [224].